Robert Spignesi: Yes. It’s very low. I think it’s specifically around China. Yes, so our connectivity and exposure is quite low. We have a strong CDMO footprint, I think as you know. Our value prop resonates strongly there, but our current products and our expected customer base would be independent of that BIOSECURE Act and the named parties within.
Steven Mah: Okay. I appreciate that color. And last one is a follow-up question on Rapid Sterility. Can you just walk through some of the positive early beta testing feedback and the stress testing that you did during that beta launch that’s driving confidence in the expected midyear launch? And has Rapid Sterility helping drive the conversation with new customers? Thank you.
Robert Spignesi: Yes. So in reverse order, we — it is helping drive conversations with new customers and existing customers. So we’ve been — I wouldn’t say surprised because we expected a positive response, and we’re getting it. And I think it’s important to note that there’s — we have not assumed meaningful contribution for Sterility and our 2024 guide, just given the midyear launch and the sales cycle timing. But we’re certainly going to preserve the opportunity to have upside with regard to Sterility. And there is quite a bit of excitement around it. Our confidence comes from a combination of customer feedback as well as rigorous development process we have internally. So that process goes through the system readiness, it’s basically a new consumable that worked with the system and a lot of testing with regard to some of the data that you’ve seen published with regard to time-to-detection and time-to-result.
And then, of course, that data, we will work with customers to ultimately over time, validate in their environments. But we’re — and where we are today, we’re quite confident in what we’re seeing and that gave us the confidence to release a press release and all of the above kind of feeds into that. Our internal data feedback from of the market research we’ve done and our internally generated data, all kind of collude together to give us that outlook and confidence to move forward. And also inbound interest from customers, also is feathering into the mix now, too, which is very exciting. So more to follow. We look forward to update you as we go forward through the quarters here. But I can say, just kind of in summary, we’re excited about the product.
And so far, the market also seems quite excited about the product as well.
Steven Mah: Okay, great. Thanks for that. And congrats again.
Robert Spignesi: Okay. Well, thanks, Steve for the question. And thanks everyone, for joining us today. Again, we enter the year with strong momentum and in a great position to deliver an excellent year in 2024. I look forward to speaking with many of you over the next few weeks at the TD Cowen and KeyBanc Life Sciences Conferences. Thank you all.
Operator: Ladies and gentlemen, this concludes today’s conference call. You may now disconnect.
